Scientists develop tumor-specific anti cancer therapy

Chinese scientists developed a combined tumor-specific anti cancer therapy therapy that can be activated specifically at tumor sites in mouse models of cancer, which is more effective than previous similar therapies.

Scientists develop tumor-specific anti cancer therapy

The study published in the journal Science Immunology described the new cancer immunotherapy that can prevent the immune system from becoming tolerant of tumors, which occurs in 30 percent of all cancer patients.

interesting reading:  Beluga whale sighted off San Diego coast mystifies scientists

A team led by Wang Dangge from Shanghai Institute of Materia Medica under the Chinese Academy of Sciences and Fudan University developed a common immune checkpoint inhibitor in a nanoparticle formulation, which is highly tumor-specific.

The checkpoint inhibitor is a kind of increasingly popular
anti-cancer drug. It can block proteins that keep immune T cells from killing cancer. But the checkpoint inhibitor used to target those immune system-suppressing proteins like PD-1 and PD-L1 often fails to reach deep-seated or metastatic tumors.

interesting reading:  China Launch Emergency Use Of Potential COVID-19 Vaccine Given To Key Worker

Wang’s team combined the nanoparticles carrying PD-L1-targeting antibodies with a light-activated molecule. The molecule called photosensitizer can produce tumor-killing anti cancer reactive oxygen species after encountering a protein abundant in tumors, according to the study.

In mouse models, a local near-infrared radiation that activated the photosensitizer, along with the administration of antibodies-carrying nanoparticles, promoted the infiltration of cancer cell-killing T cells into the tumor site and made the tumors more sensitive to the checkpoint blockade.

interesting reading:  China develops novel rabies vaccine

This combination also helped the nanoparticles effectively suppress tumor growth and metastasis to the lung and lymph nodes, resulting in approximately 80 percent mouse survival over 70 days, compared to complete mouse death in 45 days in the group treated with only PD-L1 antibodies, according to the study.

READ MORE:

Leave a Reply

Your email address will not be published. Required fields are marked *

Captcha loading...

blank